M&A Deal Summary

Agenus Acquires PhosImmune

On December 23, 2015, Agenus acquired life science company PhosImmune

Acquisition Highlights
  • This is Agenus’ 3rd transaction in the Life Science sector.
  • This is Agenus’ 2nd transaction in the United States.
  • This is Agenus’ 1st transaction in Virginia.

M&A Deal Summary
Date 2015-12-23
Target PhosImmune
Sector Life Science
Buyer(s) Agenus
Deal Type Add-on Acquisition

Target

PhosImmune

Charlottesville, Virginia, United States
PhosImmune, Inc. is a developer of therapeutic cancer vaccines.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Agenus

Lexington, Massachusetts, United States
Category Company
Founded 1994
Sector Life Science
Employees389
Revenue 156M USD (2023)
DESCRIPTION

Agenus is a biotechnology company developing treatments for cancers and infectious diseases. Agenus was incorporated in 1994 and is based in Lexington, Massachusetts.

DEAL STATS #
Overall 3 of 3
Sector (Life Science) 3 of 3
Type (Add-on Acquisition) 2 of 2
State (Virginia) 1 of 1
Country (United States) 2 of 2
Year (2015) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-04-08 Celexion - Key Antibody Assets

Cambridge, Massachusetts, United States

Celexion's Key Antibody Assets is a SECANT yeast display platform for the generation of novel monoclonal antibodies. SECANT is designed to enable highly efficient interrogation of drug targets such as checkpoint proteins.

Buy $4M
Mergr

Product

Company

Legal